Neuroprotective effect of selected lactic acid bacteria combination in a mouse model of parkinsonism under treatment with levodopa-benserazide

PEREZ VISÑUK, DAIANA; LEBLANC, JEAN GUY; DE MORENO DE LEBLANC, ALEJANDRA

Chapadmalal

Congreso; XVIII Congreso de la Sociedad Argentina de Microbiología General; 2023

Sociedad Argentina de Microbiología General

Parkinson?s disease (PD) patients show alterations in the gut microbiota composition. Alteration of the microbiota-gut-brain axis has been associated with specific microbial products related to intestinal and neuronal inflammationFurthermore, dysbiosis may also be associated with the low levels of certain vitamins observed PD patients. The aim of this work was to study the neuroprotective mechanisms associated with the administration of a mixture (MIX) of lactic acid bacteria (LAB) composed by Lactiplantibacillus plantarum CRL2130 (riboflavin overproducing strain), Streptococcus thermophilus (St.) CRL808 (folate producer strain), and St. CRL807 (immunomodulatory strain) in a chronic model of parkinsonism under levodopa-benserazide treatment. Parkinsonism was induced with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, in combination with probenecid) in C57BL/6 mice. . After the fifth dose, the mice strated levodopa-benserazide oral treatment. Throughout the trial, LAB MIX was administered orally in the test groups and the control groups received physiological solution or comercial vitamins. Motor tests were performed during the model, tyrosine hydroxylase (TH) positive cells were evaluated in the brains by immunohistochemistry, The study of the microbiota was performed in stool samples, cytokine profiles were evaluated in brain and blood samples, and the histology of the small intestine was also evaluated.The results showed the neuroprotective effect associated with the administration of the LAB MIX, which did not interfere with levodopa-benserazide treatment. These benefitswere associated with a significant decrease (p